generation of inducible pluripotent stem cells-University of Alabama at Birmingham

This is a cell therapy research program developed at the University of Alabama at Birmingham (UAB) focusing on the treatment of diabetic retinopathy and macular ischemia. The approach involves generating human induced pluripotent stem cells (hiPSCs) from the peripheral blood of diabetic patients and healthy controls. These hiPSCs are then differentiated into vascular reparative cells, specifically mesoderm cells, CD34+CD45+ hematopoietic cells, and endothelial colony-forming cells (ECFCs). The therapeutic goal is to inject these cells into the vitreous cavity to promote the repair of degenerated retinal capillaries and restore vascular function through cell replacement and paracrine signaling. The program is led by researchers including Maria Grant, Michael Boulton, and Mervin Yoder.

Other names

Human iPSC for Repair of Vasodegenerative Vessels in Diabetic RetinopathyhiPSC-derived vascular reparative cellshiPSC-derived mesoderm cellshiPSC-derived CD34+CD45+ cellshiPSC-derived endothelial colony-forming cells